33
Participants
Start Date
April 30, 2012
Primary Completion Date
July 31, 2014
Study Completion Date
December 31, 2014
UT-15C SR
Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
University of Rochester, Rochester
University of Pittsburgh Medical Center (UPMC), Pittsburgh
The Ohio State University, Columbus
Washington University School of Medicine, St Louis
Arizona Pulmonary Specialists, Phoenix
University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson
Lead Sponsor
United Therapeutics
INDUSTRY